dc.creator | BASSO, Fernanda Goncalves | |
dc.creator | BOER, Camila Cominato | |
dc.creator | CORREA, Maria Elvira Pizzigatti | |
dc.creator | TORREZAN, Marcia | |
dc.creator | CINTRA, Maria Leticia | |
dc.creator | MAGALHAES, Marina H. C. Gallottini de | |
dc.creator | SANTOS, Paulo da Silva | |
dc.creator | SOUZA, Carmino Antonio de | |
dc.date.accessioned | 2012-10-19T23:40:03Z | |
dc.date.accessioned | 2018-07-04T15:19:48Z | |
dc.date.available | 2012-10-19T23:40:03Z | |
dc.date.available | 2018-07-04T15:19:48Z | |
dc.date.created | 2012-10-19T23:40:03Z | |
dc.date.issued | 2009 | |
dc.identifier | SUPPORTIVE CARE IN CANCER, v.17, n.4, p.465-468, 2009 | |
dc.identifier | 0941-4355 | |
dc.identifier | http://producao.usp.br/handle/BDPI/24936 | |
dc.identifier | 10.1007/s00520-008-0536-8 | |
dc.identifier | http://dx.doi.org/10.1007/s00520-008-0536-8 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1621662 | |
dc.description.abstract | Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph(+) in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy. | |
dc.language | eng | |
dc.publisher | SPRINGER | |
dc.relation | Supportive Care in Cancer | |
dc.rights | Copyright SPRINGER | |
dc.rights | restrictedAccess | |
dc.subject | Imatinib mesylate | |
dc.subject | Oral lesions | |
dc.subject | Skin lesions | |
dc.subject | Side effects | |
dc.title | Skin and oral lesions associated to imatinib mesylate therapy | |
dc.type | Artículos de revistas | |